DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France.

Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

[1][2][3][4][5][6] DBV Technologies was founded in 2002 by Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).

[1][3][4][17] The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration.

The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy.